Similarly, treatment with the NAT10 inhibitor Remodelin also reduced CDK2, CDK4, CyclinD1, and Cyclin E expression and increased the expression of p16 and p21 in the two AML cell lines (Figures 3C, D). This evidence concerns the gene NAT10 and acute myeloid leukemia.